There’s good news and some bad news said Amarin Corporation (AMRN) to investors today, using the carrot and the stick approach.The maker of the fish oil drug Vascepa released positive preliminary sales outlook for 2019, which appear likely to reach the top or possibly slightly higher end of management’s guidance ($425 million).In less positive news, the company also released its operating expense (Opex) guidance for 2020. Currently, 2019 consensus Opex estimates are for roughly $350 million, while 2020 will see an increase in the region of $200-$250 million, indicating levels of between $550-$600 million. At present, the 2020 Opex estimate …read more
Source:: Yahoo Finance
